Tuesday , January 31 2023

They are making progress in treating diabetes


Researchers at Icahn Medical Research in Mount Sinai, USA, found the combination of two herbal medicines, the most commonly observed spread of insulin-induced pancreatic cancer cells. As a result, it is a significant step towards diabetes, which allows the production of insulin in the body.

There was a drug that inhibits the DYRK1A enzyme and a substance that inhibits TGFbetaSF. Together, cells are spreading at a rate of 5-8 per cent per day, the "Cell Metabolism" & quot; published in an article in this article.

Andrew Stewart, the lead author of the study, says: "We are very excited about this new observation, because beta-cell replication rates in human cells are enough to increase the mass of beta cells in humans, for the first time, Sinai Mountain, Director of the Obesity and Metabolism Institute. I've found a combination of medicines that are relevant for renewal. The next major barrier can be directed directly to the pancreas? "He explains.

According to Stewart, no diabetes medicines in the market today can lead to the recovery of beta cells from diabetic people. In parallel with the work on the Sinai mountain, other researchers are engaged in the replacement of beta-cell stem cells for pancreatic transplantation, beta-cell transplantation, and diabetes, but none of these methods are widespread.

Diabetes occurs when there are not enough beta cells in the pancreas, or when these beta cells are less insulin, the hormone needed to maintain normal levels of blood sugar levels.

The loss of beta-producing insulin cells is known as the cause of type 1 diabetes, which for a long time is an attack of the immune system and destroys beta cells. In recent years, scientists have come to the conclusion that the lack of functioning beta cells has the greatest impact on type 2 diabetes, the most common type among adults. The development of drugs that can increase the number of healthy beta cells is a priority.

In Nature Medicine, in 2015, the same team demonstrated that a drug called a loss has led to a continuous split in culture and mature human beta cells. In addition, malignant treatments led to normal blood glucose control in beta cells replacing human beta cells. Although this was a significant improvement, the spread rate was lower than needed. In 2017, Stewart and his team published a second article in "Nature Communication". In these insulinomas, a benign human has revealed genetic abnormalities with beta-cell tumor and serves as a "genetic prescription." They now offer a combination of two pharmaceuticals to enhance the recovery of beta cells by utilizing the "genetic prescription" of insulinoma. It turned out to be true, but this new drug is not an obstacle. "Since these drugs have an effect on other body organs, we must develop methods to deliver these drugs especially to beta cells," says Stewart. "We have a package, but we need a messaging system to deliver them to the exact cell of the beta cell".

Source link